Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erik Maki

Vascular & Interventional Radiology Carson City, NV Medical Doctor

NPI 1619266632 CMS profile 4148229

2874 N Carson St Ste 300, Carson City, NV 89706

Open in the dashboard

General payments

$4,829

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erik Maki of Carson City, NV is reported in the CMS Open Payments database as having received $4,829 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $388 11
2024 General $688 38
2023 General $769 24
2022 General $666 15
2021 General $895 19
2020 General $671 26
2019 General $752 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erik Maki
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Erik Maki were reported at $388. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Erik Maki Vascular & Interventional Radiology median Middle half National median
2019 $752 $422 $125–$1,555 $163
2020 $671 $200 $68–$652 $114
2021 $895 $280 $99–$866 $132
2022 $666 $433 $137–$1,497 $149
2023 $769 $506 $152–$2,019 $160
2024 $688 $556 $175–$1,930 $164
2025 $388 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,312 38 payments
  2. Boston Scientific Corporation $1,083 52 payments
  3. Inari Medical, Inc. $735 12 payments
  4. Medtronic USA, Inc. $511 17 payments
  5. Stryker Corporation $455 7 payments
  6. Abbott Laboratories $326 13 payments
  7. Shockwave Medical, Inc $88 3 payments
  8. AngioDynamics, Inc. $59 1 payment
  9. Argon Medical Devices, Inc. $48 2 payments
  10. Terumo Medical Corporation $47 2 payments
  11. Other $166 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,829 154 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $691 7 payments
  2. KYPHON Balloon Kyphoplasty $511 17 payments
  3. KYPHON EXPRESS II KYPHOPAK TRAY $438 12 payments
  4. CT THROMBECTOMY SYSTEM KIT $414 3 payments
  5. BIO DBM $274 3 payments
  6. ClotTriever $182 7 payments
  7. FlowTriever $182 7 payments
  8. OSTEOCOOL RF ABLATION SYSTEM $177 7 payments
  9. OSTEOCOOL RF ABLATION $150 3 payments
  10. AVVIGO Guidance System $139 11 payments
  11. Other $2,287 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 242 billing codes

Paid by Medicare

$157,626

Of which drugs: $885

Medicare patients

2,573

Average age 75

Services billed

11,395

1,432 women, 1,141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 34%
Diabetes 30%
Chronic kidney disease 29%
COPD 28%
Atrial fibrillation 25%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 82 7,380 $806

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record